A Simple Key For ABBV-744 BRD4 inhibition in cancer cell lines Unveiled
In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will receive treatment until finally illness progression or perhaps the participants are not able to tolerate the study drugs.General, our existing work highlights the potential utilization of ARV-825 in com